PDCD1 and esophageal squamous cell carcinoma: Recently, a multicenter, retrospective, real‐world clinical study showed that mPFS and mOS were 5.6 and 11.1 months in previously ICI‐treated advanced ESCC patients who received anlotinib plus PD‐1 inhibitors treatment [55].